frozen expressions. 7, 8 Although generally not serious, these effects can last for weeks or months and be very distressing for patients.
Therefore, it is essential that treating physicians have the highest level of understanding of facial muscular anatomy, precise injection technique, and an appreciation for the aesthetic result desired by the patient. Variables to consider prior to treatment include the anatomical area to be treated, gender, muscle mass, ethnicity, skin thickness, and the effects of aging. 9 Bilateral differences may exist in the same patient. 10 The following Advanced Botulinum Toxin Application (ABTA) algorithm has been used by the author since 2012 with excellent results and is based, in part, on a review of the literature. [11] [12] [13] [14] [15] Only one type of BTX was used (onabotulinumtoxinA; Botox ® ; Allergan, Inc, Sao Paulo, Brazil). Prior to BTX application, digital images of patients were obtained while relaxed and while forming different facial expressions. This information was used to plan the depth (Figure 1 ), dose, and location of BTX application. The dilution was 100 U of BTX to 1 mL 0.9% preserved saline, and applications were made using 30 U insulin syringes fitted with 30 gauge needles.
| TRE ATMENT ALG ORITHM

| Glabella (corrugator supercilii m., procerus m., orbicularis oculi m., and frontalis m.)
There can be five patterns of glabellar contraction, three of them represented in Figure 2 . 16 The most common type is V-shaped. Each pattern requires a different distribution of BTX injection points with a different dose and injection depth (Figures 2 and 3 ) to achieve beneficial and longlasting effects (Figures 1-5 ).
• The first step is to evaluate the width of the glabella area, or the distance between the two corrugator muscles (intraglabellar width; IGW). If the IGW is wide, the dose of BTX in the procerus m.
should be conservative using 2.5-5 U in one or two sites ( Figure   4A ,B), depending of the participation of the depressor superciliae or medial aspect of orbicularis oculi. If the IGW is normal or small, the dose should be 5-10 U (Figure 4A -D).
• Determine whether the m. depressor supercili and/or medial aspect of orbicularis oculi participates in depressing the head of the brows, giving an angry look. When the patient frowns really hard, determine if there are wrinkles in the medial orbital rim down to the lateral nasal wall ( Figure 4C,D) . If present, inject the procerus m. at two points using a dose of 2.5 U per point or inject the m.
procerus at one site in the center with 5 U and superficial injections 3 mm from the center using 2 U at each point.
• Determine if the orbicularis oculi is also playing a role. When the patient squeezes their eyes shut, that is helping the corrugators to depress the mid-brow. This is apparent if small wrinkles form behind the tail of corrugator. Superficially inject 1-2 U right above the brow ( Figure 4E ,F).
• Determine also if the frontalis m. is playing a role in contracting the head of the corrugators. This is apparent when the patient frowns strongly and wrinkles in the middle of the IGW can be seen. Inject 1-2 U at two points 4 mm from the center of the IGW ( Figure 5A ).
| Forehead (frontalis m.)
The forehead is one of the most difficult areas to treat because it is a large muscle with four main patterns of contraction according to the insertion and shape of aponeurosis of frontalis m (Figures 1 and 6-10) . 17 In addition, the forehead may vary in symmetry on different sides in the same person. The most common muscle movement is total contraction and aponeurosis very high up in the forehead (Type IV). The lateral aspect of the muscle is a challenge to treat and often needs to be combined with volume restoration to have a effective outcome in this area ( Figure 7 ).
• First, consider whether the patient requires frontalis strength to maintain brow position to lift upper eyelid in cases of brow ptosis. This is apparent if the patient opens their eyes with a relax forehead and the frontalis m. contracts. In that case, the total dose of BTX should be decreased to no more than 6-8 U (Figure 8 ). If this is not the case, use a total dose of 6-15 U (Figure 9 ).
• Determine whether the patient has medial or central brow ptosis. If present, use a very low dose in the mid-frontalis (the active part of frontalis muscle used for brow elevation). Do not superimpose the injection points in the same vertical line with the first corrugator points.
Perform more superficial injections using 1 U per site ( Figure 9A,B) . 
| Periocular area (orbicularis oculi m.)
This is a large circumferential muscle that works with other muscles to create facial expression. It is related anatomically to the zygomatic muscles when smiling, corrugator muscles when frowning, and nasalis muscle when blinking. 12 There are several patterns of contraction. 12 Figure 11A ,B demonstrates a method for distributing the injections to block the depressor effect of the orbicularis m. Zygomatic wrinkles may have more to do with volume loss than isolated muscle contraction.
12
• There are four main considerations when evaluating the orbicularis oculi to ensure a more harmonic and natural look. If wrinkles appear below lateral aspect of the brow when the patient squeezes their eyes shut, consider superficial injections of 1-2 U at one or two injection sites.
• If the end of the brow is pulled down during a big smile, the first injection point should be put higher and use 7 U instead of 5 U on each side.
• If zygomatic wrinkles are present when the patient smiles, inject 0.5-1 U in one or two points in the superior aspect of the zygomatic arch. If no wrinkles are present, inject 2 U into each side.
The presence of wrinkles suggests that facial deflation is present so one must be conservative when treating this area in order not to create an unnatural smile.
• Determine if the lower eyelid is lax or if blepharochalasis is present. If wrinkles in the inner canthus are present, they should be injected at one point on each side using 0.5-1 U. If there is no eyelid laxity and the patient has wrinkles in lateral orbital rim, then one additional point can be added on top of each side using 1 U.
If the patient wishes to enhance aperture of the eye, then 0.5-1 U can be injected in one point on either side of the central pre-tarsal orbicularis area.
| Lower face (mentalis m., depressor anguli oris m., orbicularis oris m.)
These are small muscles located very close to one other. They are especially important in patients with retrognatism or hypognatism.
Also important is the role of fat loss in these areas which contrib- • When the patient makes an effort to contract the neck and mouth, it can be seen if the corners of the mouth are pulled down.
Sometimes (when platysma m. insertion is high) diverse pattern wrinkles in the lateral inferior aspect of lower face can be seen. If • If the tip of the nose is drawn down when smiling, the depressor of nasal septae m. should receive 2-4 U in one deep injection in the base of the columella.
| Mastigators (masseter m., temporalis m.)
These muscles have primarily a chewing function but may play an important role in lower facial expression. The masseter is a triventral muscle, and hypertrophy can produce a masculine look in women. Therefore, decreasing muscle hypertrophy can influence in facial contour. The temporal muscle is a large, fan-shaped muscle, and hypertrophy can cause a widened forehead look. When atrophied in old men, it gives an aspect of skeletonization of forehead and temple.
• Muscle hypertrophy can be palpated when the patient clenches their teeth. Delineate the borders of the masseter during contraction and divide the muscle vertically into thirds. Two points should be injected in the lower third, 5-10 mm apart, and one in the center of the middle third 5-10 mm from the other sites.
If mild hypertrophy not associated with headaches is present, inject 5 U at each point. If hypertrophy is greater or associated with headaches, inject 10 U at each lower point and 5 U in the upper point.
• For hypertrophic temporal m. not associated with headaches, the injection should be done in a line parallel to the temporal fusion line 5 cm above zygomatic arch at three points 10 mm apart using 2 U per site. If temporal hypertrophy is associated with headaches, inject the same sites using 5 U per site. • The block should be done only to the platysmal bands that are very evident and it should be done deep to the muscle. If the block is too strong, the neck will lose adipose support. If the block is too superficial, no effect in the platysma m. will be seen.
| Neck (depressor
| Comparative study
To evaluate the improvement we can have through the use of the botulinum toxin algorithm (ABTA), the author compared the clinical results of 500 patients treated with BTX before using the algorithm described above (No ABTA) and 500 patients after using it. Specific areas studied were the glabella, orbicularis oculi, and the frontalis. Among patients in both groups, a similar number had undergone prior treatment with BTX (n = 204; 40.5%). The mean doses of BTX used and the mean number of treatment points are summarized in Table 1 . Visual results are shown in Figure 12A ,B.
A comparison of mean doses used showed significantly higher doses of BTX were used in glabella, orbicularis, and frontalis during the first treatment when using the ABTA (P < 0.0001; Table 2 ). As a result, the mean doses were significantly lower during the Day 15 retreatment (P < 0.0001). Overall, BTX doses were significantly higher for the glabella and frontalis when using the ABTA (P < 0.0001).
Similarly, a significantly higher number of treatment points were used in the glabella, orbicularis, and frontalis during the first treatment when using the ABTA (P < 0.0001) but significantly fewer during the 15-day retreatment (P < 0.0001; Table 3 ). Overall, the number of treatment points was significantly higher for the glabella and frontalis when using the ABTA (P < 0.0001). Table 4 ) and overall patient satisfaction remained high after 6 months (479 vs 195 patients, P < 0.0001).
Use of the ABTA had little effect on the occurrence of adverse events. A similar number of patients in each group developed treatment-related echymosis (n = 22; 4.4%).
| D ISCUSS I ON
The treatment algorithm described here has been used by the author for facial rejuvenation for more than 5 years. It was originally based on recommendations and guidelines obtained from published aesthetic dermatology literature. 9,12,13 By carefully noting treatment outcomes, the number and location of injection points and the dose of BTX used have been modified to create the current treatment system. It is interesting to note that the BTX doses described here differ from previously published consensus guidelines. 9, 18 A comparison of the doses used here and other treatment guidelines is shown in Table 1 . These differences are due to technique which are also likely to evolve over time for each practitioner.
Each treatment plan needs to be customized for each patient.
To ensure good treatment outcome with BTX, it is important to understand how to evaluate each muscle and how they may vary from patient to patient. Differences may include muscle mass due to age or gender which will require different doses of BTX to ensure muscle block. It is also important to be careful when evaluating muscles that can contract in different patterns. In addition to dose, the depth of BTX injections is important because it affects the extent of drug diffusion. It may also increase the risk of complications when injecting the upper brow, corrugators and zygomatic arch wrinkles.
The algorithm use resulted in more precise injections with almost no need for glabellar touch ups in 15 days. The orbicularis region showed greater reduction in touch ups needed after 15 days as did forehead.
Even with a better understanding of forehead muscle strength, and depth and distribution of injection points according to contraction patterns, it is still a difficult task to get balance between ideal injection points and patient satisfaction; however, patients treated using the algorithm showed greater satisfaction levels. Also, according to a recent consensus on doses per treatment area, higher doses and better distribution are needed to achieve greater duration and satisfaction with aesthetic results.
| CON CLUS ION
Published guidelines for the use of BTX are an excellent starting point for clinicians with little experience; however, each practitioner will likely develop their own algorithm for achieving good facial rejuvenation outcomes. It is hoped that the recommendations provided here will help others to achieve treatment success.
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E N D N OTE S
a Only onabotulinumtoxinA was available at that time.
O RCI D
Gabriela Casabona http://orcid.org/0000-0002-3183-0432
